Navigation Links
Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
Date:6/2/2008

abine for five days.

Preliminary data for this trial were previously announced at the American Society of Hematology Annual Meeting in December 2007.

About Vion

Vion Pharmaceuticals, Inc. is committed to extending the lives and improving the quality of life of cancer patients worldwide by developing and commercializing innovative cancer therapeutics. Vion has two agents in clinical trials. Cloretazine(R) (VNP40101M), a unique alkylating agent, is being evaluated in a Phase II pivotal trial as a single agent in elderly patients with previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Cloretazine(R) (VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
2. Jazz Pharmaceuticals, Inc. Completes Enrollment in First of Two Phase III Clinical Trials of Sodium Oxybate to Treat Fibromyalgia
3. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
4. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
5. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
6. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
7. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
8. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
9. QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy
10. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
11. Tioga Pharmaceuticals Asimadoline Demonstrates Positive Results in a Phase 2b Clinical Trial for the Treatment of Irritable Bowel Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers ... board of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ... per share. Concerned SLXP investors are encouraged to contact ... The investigation focuses upon the shareholder value ... Salix shareholders would receive only $158.00 per share in ...
(Date:2/27/2015)... -- Boston Scientific Corporation (NYSE: BSX ) is ... Conference on March 10 in Miami Beach ... vice president and chief financial officer, and Susie ... a 25-minute question and answer session regarding the company ... Following a 5-minute break, a question and answer session ...
(Date:2/27/2015)... MISSISSAUGA, ON , Feb. 27, 2015 /CNW/ - Covalon ... advanced medical technologies company, today announced financial results for ... For the three months ended December 31, 2014, ... for the quarter was $229,820 or $0.02 per share.  ... Pedlar , said "I am very pleased with the ...
Breaking Medicine Technology:Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2Covalon Announces First Quarter Financial Results 2Covalon Announces First Quarter Financial Results 3
... NEW YORK, Aug. 14 Immtech Pharmaceuticals,Inc. (Amex: ... paper published in Nucleic,Acids Research by a group ... ability of furamidine to inhibit a key enzyme ... Furamidine is the active metabolite (DB75),of Immtech,s proprietary, ...
... Scheduled Start of Phase 3 Clinical Trial, BELTSVILLE, ... has reported a second quarter 2007 loss from continuing,operations ... to a loss from,continuing operations of $699,000, or 5 ... from discontinued operations in the second quarter,of 2007 was ...
Cached Medicine Technology:Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 2Furamidine Found to Inhibit a Key Enzyme Involved in Cancer Cell DNA Repair Mechanisms 3Spherix Reports Second Quarter Earnings 2
(Date:2/28/2015)... In recent years Medical Marijuana has continuously been ... a way for them to expand their patient base without ... Since the FDA still lists Cannabis as a Schedule 1 ... physicians that can help guide them when recommending a ... in Santa Cruz, CA is a leader in the small, ...
(Date:2/28/2015)... AB (PRWEB) February 28, 2015 The ... is now a distributor of the machine. The Heart ... of their license, like a franchise model. The goal ... prevent and reverse heart disease. To buy External ... Fit Clinic can help individuals through this process and ...
(Date:2/28/2015)... NB (PRWEB) February 28, 2015 ... center software suite for Asterisk, are pleased to announce ... highly successful 5.7 and 5.8 versions of Q-Suite, this ... well as a number of new features to the ... Q2 2015. , Q-Suite 5.9 will add features to ...
(Date:2/28/2015)... 28, 2015 National Sales ... sales, marketing and supply chain management for consumer ... is bringing its award winning solutions for thinning-damaged ... products are specifically created to combat thinning-damaged hair. ... is committed to marrying science with nature to ...
(Date:2/28/2015)... 28, 2015 How would you ... , There are all kinds of different leaders, ... awareness of the advantages and applications of different ... launching a new product this spring called The ... the connection between personality type, leadership, and success. ...
Breaking Medicine News(10 mins):Health News:Reputable Cannabis Doctor In Santa Cruz and Monterey Joins the Medical Cannabis Network 2Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Indosoft Proudly Announces Q-Suite 5.9 Call Center Software for Asterisk 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3Health News:PeopleKeys Launches The Leadership Report 2Health News:PeopleKeys Launches The Leadership Report 3
... be "alarmingly dismal" with over 180 million urban poor having ... an industry analysis. ,At least 300 additional urban ... annually to cater to the needs of 215 million urban ... of Commerce and Industry of India (ASSOCHAM). ,In ...
... of colorectal cancers getting missed out in patients undergoing ... a gastroenterologist// or a surgeon. This was disclosed by ... researchers. ,This study was conducted on 12,487 ... Ontario along with her team. According to this study, ...
... flu in their county. This was disclosed by Faizullah Kakar, ... H5N1 virus was found in the eastern province of Nangarhar. ... diagnosed as the case of malaria. The Nangarhar area has ... ,Culling of birds was initiated earlier this week ...
... risk of mercury in canned albacore tuna in women and ... tuna in women and children. This follows a recent report ... cans of albacore tuna tested contained mercury more than the ... of canned albacore tuna per week can be had by ...
... and intolerance to gluten.// ,Inflammatory ... inflammations in muscular tissue. Coeliac disease is ... ,Inflammatory myopathies are inflammatory infiltrates ... includes polymyositis, dermatomyositis, and inclusion-body myositis. Little ...
... the heart gets its distinguishing shape? Shape may be formed ... and shape, all of which react to// influences from the ... bulges later on to develop into cardiac chambers. ... journal PLoS Biology, Heidi Auman, Deborah Yelon, and colleagues found, ...
Cached Medicine News:Health News:Urban Poor in Dire Need of Proper Healthcare: Report 2Health News:Inflammatory Myopathy may Indicate Intolerance to Gluten 2
Donor Screen & Confirmation Kit...
... method for Dimension integrated chemistry systems ... in vitro diagnostic test intended to ... (TPSA) in human serum or plasma. ... in the detection of prostate cancer ...
... Wampole Laboratories offers a comprehensive line of ... serum and urine in convenient one-step stick ... 2 testing options. Clearview Easy HCG is ... convenient stick format. Clearview HCG II ...
The BioCheck hCG ELISA is intended for the quantitative determination of human chorionic gonadotropin (hCG) concentration in human serum. The assay is for use in the early diagnosis of pregnancy in a...
Medicine Products: